Beam Therapeutics (BEAM) Assets Average (2020 - 2026)

Beam Therapeutics (BEAM) has reported Assets Average for 7 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 15.22% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 15.22% YoY), while the FY2025 annual figure was $1.3 billion, up 0.84% from the prior year.
• Assets Average climbed to $1.5 billion in Q1 2026 per BEAM's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.5 billion in Q1 2026 and bottomed at $1.1 billion in Q4 2024.
• Historically, Assets Average has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2025.
• Annual changes were most pronounced in 2022 — Assets Average jumped 155.73% — and 2024, when it declined 17.27%.
• Beam Therapeutics' Assets Average stood at $1.3 billion in 2022, then grew by 2.17% to $1.4 billion in 2023, then slipped by 17.27% to $1.1 billion in 2024, then increased by 22.73% to $1.4 billion in 2025, then rose by 6.08% to $1.5 billion in 2026.
• Business Quant data shows BEAM's Assets Average at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.